Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Weisman

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Nature Chemistry|June 24, 2017
A polymer nanoparticle with engineered affinity for a vascular endothelial growth factor (VEGF<sub>165</sub>)Hiroyuki Koide, Keiichi Yoshimatsu, Yu Hoshino, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 22, 2024
Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagementDorene M Rentz, Paul S Aisen, Alireza Atri, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Nature Chemistry|June 24, 2017
A polymer nanoparticle with engineered affinity for a vascular endothelial growth factor (VEGF<sub>165</sub>)Hiroyuki Koide, Keiichi Yoshimatsu, Yu Hoshino, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 22, 2024
Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagementDorene M Rentz, Paul S Aisen, Alireza Atri, et al.
Pageof 2